4[8]Scagliotti GV,De Marinis F,Rinaldi M,et al.Phase Ⅲ randomized trial comparing three platinum - based doublets in advanced non - small cell lung cancer [J].J Clin Oncol,2002,20 (21):4285 ～ 4291.
5[10]Nartoni A,Narino A,Sperandi F,et al.Multicentre randomized phase Ⅲ study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non - small cell lung cancer [J].Eur J Cancer,2005,41 (1):81 ～92.
6[2]Socinski NA.Cytotoxic chemotherapy in advanced non - small cell lung cancer:a review of standard treatment paradigms [J].Clin Cancer Res,2004,10(2):4210 ～4214.
7[3]Sandler AB,Nemumaitis J,Denham C,et al.Phase Ⅲ trial of gecitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non - small cell lung cancer [J].J Clin Oncol,2000,18:122 ～ 130.
8[4]Hotta K,Matsuo K,Ueoka H,et al.Addition of platiinum compounds to a new agent in patients with advaned non - small cell lung cancer:a literature based meta -analysis of randomised trials[J].Ann Oncol,2004,15(12) :1782 ～1789.
9[5]Cardenal F,Lopez - Caberizo M,Anton A,et al.Randomized phase Ⅲ study of gemcitabine - cisplatin versus etoposide - cisplatin in the treatment of locally advanced or metastatic non - small cell lung cancer[J].J Clin Oncol,1999,17:12 ～ 18.
10[6]Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non - small cell lung cancer[J].N Engl J Med,2002,346:92 ～98.
7Aydogan S, Celiker U, Turkcuoglu P, el al. The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in reti- nal ischemia/repeffusion injury[J]. Graefes Arch Clin Exp Ophthalmol,2008, 246 (3): 363-368.
8Vasvari GP, Dyckhoff G, Kashfi F, et al. Combination of thalidomide and cisplatin in a head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo [J]. int J Cancer, 2007, 121 (8): 1697-1704.
9Jin SH, Kim TI, Yang KM, et al. Thalidomide destabilizes eyelooxygenase- 2 mRNA by inhibiting p38 mitogen-aeti- vated protein kinase and cytoplasmic shuttling of Hutl [J]. Eur J Pharmaeol, 2007, 558(1-3): 14-20.
10Efstathiou E, Troneoso P, Wen S, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer [J]. Clin Cancer Res, 2007, 13(4): 1224-1231.
